Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19

PHASE4CompletedINTERVENTIONAL
Enrollment

1,000

Participants

Timeline

Start Date

May 13, 2020

Primary Completion Date

April 29, 2021

Study Completion Date

September 14, 2021

Conditions
COVIDThrombosisPulmonary EmbolismDeep Vein Thrombosis
Interventions
DRUG

Enoxaparin

"For example (Enoxaparin):~* 4000IU twice a day in patients \<50kg~* 5000IU twice a day in patients 50-70kg~* 6000IU twice a day in patients 70-100kg~* 7000IU twice a day in patients above 100kg"

DRUG

Enoxaparin

For example (Enoxaparin): From 4000IU once a day in patients admitted in medical ward to 4000IU twice a day in patients admitted in the ICU. In patients with severe renal insufficiency (GFR=15-30 mL/min/1.73m²), LMWH doses will be reduced by 50%.

Trial Locations (17)

Unknown

Amiens Academic Hospital, Amiens

Besançon Academic Hospital, Besançon

Brest Academic Hospital, Brest

Civil Hospital, Colmar

Dijon Academic Hospital, Dijon

Kremlin Bicêtre Academic Hospital, Le Kremlin-Bicêtre

Lille Academic Hospital, Lille

Groupe Hospitalier Unéos, Metz

Metz-Thionville Regional Hospital, Metz

Montpellier Academic Hospital, Montpellier

Emile Muller Hospital, Mulhouse

Nancy Academic Hospital, Nancy

George Pompidou European Hospital, Paris

Lariboisière Academic Hospital, Paris

St Etienne Academic Hospital, Saint-Etienne

Strasbourg Academic Hospital, Strasbourg

Toulouse Academic Hospital, Toulouse

All Listed Sponsors
collaborator

Ministry of Health, France

OTHER_GOV

collaborator

Grand Est Region

UNKNOWN

collaborator

University Hospital of Saint-Etienne

OTHER

lead

Central Hospital, Nancy, France

OTHER

NCT04373707 - Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19 | Biotech Hunter | Biotech Hunter